Circulating Vitamin D and Colorectal Cancer Risk: An International Pooling Project of 17 Cohorts.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
01 02 2019
01 02 2019
Historique:
received:
22
11
2017
revised:
26
02
2018
accepted:
16
04
2018
pubmed:
19
6
2018
medline:
12
3
2020
entrez:
19
6
2018
Statut:
ppublish
Résumé
Experimental and epidemiological studies suggest a protective role for vitamin D in colorectal carcinogenesis, but evidence is inconclusive. Circulating 25-hydroxyvitamin D (25(OH)D) concentrations that minimize risk are unknown. Current Institute of Medicine (IOM) vitamin D guidance is based solely on bone health. We pooled participant-level data from 17 cohorts, comprising 5706 colorectal cancer case participants and 7107 control participants with a wide range of circulating 25(OH)D concentrations. For 30.1% of participants, 25(OH)D was newly measured. Previously measured 25(OH)D was calibrated to the same assay to permit estimating risk by absolute concentrations. Study-specific relative risks (RRs) for prediagnostic season-standardized 25(OH)D concentrations were calculated using conditional logistic regression and pooled using random effects models. Compared with the lower range of sufficiency for bone health (50-<62.5 nmol/L), deficient 25(OH)D (<30 nmol/L) was associated with 31% higher colorectal cancer risk (RR = 1.31, 95% confidence interval [CI] = 1.05 to 1.62); 25(OH)D above sufficiency (75-<87.5 and 87.5-<100 nmol/L) was associated with 19% (RR = 0.81, 95% CI = 0.67 to 0.99) and 27% (RR = 0.73, 95% CI = 0.59 to 0.91) lower risk, respectively. At 25(OH)D of 100 nmol/L or greater, risk did not continue to decline and was not statistically significantly reduced (RR = 0.91, 95% CI = 0.67 to 1.24, 3.5% of control participants). Associations were minimally affected when adjusting for body mass index, physical activity, or other risk factors. For each 25 nmol/L increment in circulating 25(OH)D, colorectal cancer risk was 19% lower in women (RR = 0.81, 95% CI = 0.75 to 0.87) and 7% lower in men (RR = 0.93, 95% CI = 0.86 to 1.00) (two-sided Pheterogeneity by sex = .008). Associations were inverse in all subgroups, including colorectal subsite, geographic region, and season of blood collection. Higher circulating 25(OH)D was related to a statistically significant, substantially lower colorectal cancer risk in women and non-statistically significant lower risk in men. Optimal 25(OH)D concentrations for colorectal cancer risk reduction, 75-100 nmol/L, appear higher than current IOM recommendations.
Sections du résumé
BACKGROUND
Experimental and epidemiological studies suggest a protective role for vitamin D in colorectal carcinogenesis, but evidence is inconclusive. Circulating 25-hydroxyvitamin D (25(OH)D) concentrations that minimize risk are unknown. Current Institute of Medicine (IOM) vitamin D guidance is based solely on bone health.
METHODS
We pooled participant-level data from 17 cohorts, comprising 5706 colorectal cancer case participants and 7107 control participants with a wide range of circulating 25(OH)D concentrations. For 30.1% of participants, 25(OH)D was newly measured. Previously measured 25(OH)D was calibrated to the same assay to permit estimating risk by absolute concentrations. Study-specific relative risks (RRs) for prediagnostic season-standardized 25(OH)D concentrations were calculated using conditional logistic regression and pooled using random effects models.
RESULTS
Compared with the lower range of sufficiency for bone health (50-<62.5 nmol/L), deficient 25(OH)D (<30 nmol/L) was associated with 31% higher colorectal cancer risk (RR = 1.31, 95% confidence interval [CI] = 1.05 to 1.62); 25(OH)D above sufficiency (75-<87.5 and 87.5-<100 nmol/L) was associated with 19% (RR = 0.81, 95% CI = 0.67 to 0.99) and 27% (RR = 0.73, 95% CI = 0.59 to 0.91) lower risk, respectively. At 25(OH)D of 100 nmol/L or greater, risk did not continue to decline and was not statistically significantly reduced (RR = 0.91, 95% CI = 0.67 to 1.24, 3.5% of control participants). Associations were minimally affected when adjusting for body mass index, physical activity, or other risk factors. For each 25 nmol/L increment in circulating 25(OH)D, colorectal cancer risk was 19% lower in women (RR = 0.81, 95% CI = 0.75 to 0.87) and 7% lower in men (RR = 0.93, 95% CI = 0.86 to 1.00) (two-sided Pheterogeneity by sex = .008). Associations were inverse in all subgroups, including colorectal subsite, geographic region, and season of blood collection.
CONCLUSIONS
Higher circulating 25(OH)D was related to a statistically significant, substantially lower colorectal cancer risk in women and non-statistically significant lower risk in men. Optimal 25(OH)D concentrations for colorectal cancer risk reduction, 75-100 nmol/L, appear higher than current IOM recommendations.
Identifiants
pubmed: 29912394
pii: 5035027
doi: 10.1093/jnci/djy087
pmc: PMC6376911
doi:
Substances chimiques
Vitamins
0
Vitamin D
1406-16-2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
158-169Subventions
Organisme : NCI NIH HHS
ID : U01 CA063673
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA167462
Pays : United States
Organisme : NCI NIH HHS
ID : R03 CA183016
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL125232
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA182934
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA167462
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA071789
Pays : United States
Informations de copyright
Published by Oxford University Press 2018.
Références
Science. 2002 May 17;296(5571):1313-6
pubmed: 12016314
Cancer Causes Control. 2003 Feb;14(1):1-12
pubmed: 12708719
N Engl J Med. 2006 Feb 16;354(7):684-96
pubmed: 16481636
Am J Epidemiol. 2006 Jun 1;163(11):1053-64
pubmed: 16624970
Br J Cancer. 2007 Aug 6;97(3):446-51
pubmed: 17622244
Am J Physiol Gastrointest Liver Physiol. 2008 Jan;294(1):G208-16
pubmed: 17962355
Int J Cancer. 2008 Apr 15;122(8):1690-4
pubmed: 18092326
Cancer Prev Res (Phila). 2009 Jan;2(1):43-51
pubmed: 19139017
Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):130-4
pubmed: 20056631
BMJ. 2010 Jan 21;340:b5500
pubmed: 20093284
Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):927-31
pubmed: 20332255
Am J Epidemiol. 2010 Jul 1;172(1):21-35
pubmed: 20562191
Am J Epidemiol. 2011 Mar 1;173(5):499-508
pubmed: 21248311
Cancer Prev Res (Phila). 2011 May;4(5):735-43
pubmed: 21430073
Nutr Cancer. 2011;63(6):827-41
pubmed: 21774589
J Clin Oncol. 2011 Oct 1;29(28):3775-82
pubmed: 21876081
Br J Cancer. 2011 Sep 27;105(7):911-7
pubmed: 21897394
Am J Epidemiol. 2012 Apr 1;175(7):673-84
pubmed: 22362582
Scand J Clin Lab Invest Suppl. 2012;243:32-40
pubmed: 22536760
Nat Rev Immunol. 2012 Oct;12(10):696-708
pubmed: 23007570
Breast Cancer Res. 2013 Feb 26;15(1):R15
pubmed: 23442740
Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):905-16
pubmed: 23462913
Breast Cancer Res. 2013 Jun 18;15(3):R46
pubmed: 23777922
Int J Cancer. 2014 Nov 1;135(9):2135-45
pubmed: 24622914
Nat Rev Cancer. 2014 May;14(5):342-57
pubmed: 24705652
Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1220-9
pubmed: 24789846
PLoS One. 2014 Jun 20;9(6):e99954
pubmed: 24949795
Cochrane Database Syst Rev. 2014 Jun 23;(6):CD007469
pubmed: 24953955
Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):2175-80
pubmed: 25106774
Int J Cancer. 2015 Mar 15;136(6):E654-64
pubmed: 25156182
J Steroid Biochem Mol Biol. 2015 Apr;148:86-95
pubmed: 25597952
JAMA. 2015 Apr 7;313(13):1311-2
pubmed: 25695911
J Natl Cancer Inst. 2015 Mar 10;107(2):null
pubmed: 25757865
Cancer Prev Res (Phila). 2015 Aug;8(8):675-82
pubmed: 25813525
Cancer Causes Control. 2015 Oct;26(10):1449-60
pubmed: 26220152
N Engl J Med. 2015 Oct 15;373(16):1519-30
pubmed: 26465985
Stat Med. 2016 Feb 28;35(5):782-800
pubmed: 26619806
Br J Cancer. 2016 Jan 19;114(2):221-9
pubmed: 26766742
J Cancer. 2016 Jan 05;7(3):232-40
pubmed: 26918035
Int J Epidemiol. 2017 Apr 1;46(2):403-404g
pubmed: 27063606
Stat Med. 2016 Jun 15;35(13):2133-48
pubmed: 27133461
Cancer Epidemiol Biomarkers Prev. 2017 Aug;26(8):1242-1247
pubmed: 28483970
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Cancer Causes Control. 1997 Jul;8(4):615-25
pubmed: 9242478